| Literature DB >> 35160107 |
Patricia Fernández-Sanjuán1,2, Juan José Arrieta3, Jaime Sanabria4, Marta Alcaraz5, Gabriela Bosco5,6, Nuria Pérez-Martín5,6, Adriana Pérez7, Marina Carrasco-Llatas8, Isabel Moreno-Hay9, Marcos Ríos-Lago10, Rodolfo Lugo11, Carlos O'Connor-Reina12,13, Peter Baptista14, Guillermo Plaza5,6.
Abstract
Mandibular advancement devices (MAD) are an effective alternative treatment to CPAP. Different maneuvers were performed during drug sleep-induced endoscopy (DISE) to mimic the effect of MAD. Using the Selector Avance Mandibular (SAM) device, we aimed to identify MAD candidates during DISE using a titratable, reproducible, and measurable maneuver. This DISE-SAM protocol may help to find the relationship between the severity of the respiratory disorder and the degree of response and determine the advancement required to improve the collapsibility of the upper airway. Explorations were performed in 161 patients (132 males; 29 females) with a mean age of 46.81 (SD = 11.42) years, BMI of 27.90 (SD = 4.19) kg/m2, and a mean AHI of 26.51 (SD = 21.23). The results showed no relationship between severity and MAD recommendation. Furthermore, there was a weak positive relationship between the advancement required to obtain a response and the disease severity. Using the DISE-SAM protocol, the response and the range of mandibular protrusion were assessed, avoiding the interexaminer bias of the jaw thrust maneuver. We suggest prescribing MAD as a single, alternative, or multiple treatment approaches following the SAM recommendations in a personalized design.Entities:
Keywords: MAD; drug-induced sleep endoscopy; mandibular advancement; patient selection; sleep breathing disorders; titratable positioner
Year: 2022 PMID: 35160107 PMCID: PMC8836970 DOI: 10.3390/jcm11030658
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1(a) SAM device. (b) SAM titration (1–4): 0%, 50%, 75%, and 100% advancement, respectively. (c) Patient examination in supine position. (d) Patient examination in lateral decubitus position.
Figure 2UA responses to different mandibular advancements and changes in body position. UA in lateral decubitus position was analyzed with the minimum effective advancement. (a) Patient 1: the combination of MAD + positional therapy significantly improved collapsibility. (b) Patient 2: mandibular advancement was very effective in supine position at the velopharynx, but in right lateral decubitus, an epiglottis collapse appears. (c) Patient 3: multilevel collapse successfully resolved with the SAM in supine position. (d) Patient 4: mandibular advancement was not effective.
SAM recommendations (single use—alternative treatment—multiple treatment approach). * Greater predictive value in young patients, BMI < 30, without predominance of apnea in REM sleep and with predominance of obstructive hypopnea vs. apnea in the sleep study.
| S | As a single treatment if collapses are eliminated for patients with simple snoring or OSA. * |
| A | As an alternative treatment if the collapses are improved by at least 50%, from 2 to 1 or from 1 to 0, with some VOTE levels remaining at 1. Combination of therapies may improve results. Partial response expected. * |
| M | ONLY as a combined treatment. * |
| No | MAD is not recommended if no change or worsening is visualized. |
Statistical properties of the four severity groups.
| Snoring Group | Mild | Moderate | Severe | |
|---|---|---|---|---|
|
| 23 | 36 | 48 | 54 |
| Gender (m/f) | 20/3 | 25/11 | 42/6 | 45/9 |
| Mean age (SD) | 42.74 (9.65) | 46.39 (13.12) | 46.27 (11.72) | 49.42 (10.22) |
| Mean BMI (SD) | 26.06 (3.03) | 26.7 (3.22) | 27.82 (3.87) | 29.96 (4.98) |
| Mean AHI (SD) | 2.49 (1.80) | 9.01 (2.61) | 23.28 (4.41) | 51.28 (15.73) |
| Mean ESS (SD) | 8.33 (3.52) | 9.52 (5.49) | 9.21 (5.45) | 11.52 (6.09) |
AHI: apnea–hypopnea index; BMI: body mass index; ESS: Epworth sleepiness scale, M: mean; SD: standard deviation.
Proportion and number of patients classified by severity within each level of recommendation.
| Snorers | Mild | Moderate | Severe | Total | |
|---|---|---|---|---|---|
| S recommendation | 22.6 (7) | 29.0 (9) | 32.2 (10) | 16.1 (5) | 100 (31) |
| A recommendation | 14.5 (8) | 21.8 (12) | 38.2 (21) | 25.5 (14) | 100 (55) |
| M recommendation | 12.1 (4) | 21.2 (7) | 18.2 (6) | 48.5 (16) | 100 (33) |
| No recommendation | 9.5 (4) | 19.0 (8) | 26.2 (11) | 45.2 (19) | 100 (42) |
Figure 3Within each level of recommendation, the percentage of patients according to severity is shown. Note that the total for each recommendation is 100%.
Proportion and number of patients classified by recommendation within each level of severity.
| Snorers | Mild | Moderate | Severe | Total | |
|---|---|---|---|---|---|
| S recommendation | 30.4 (7) | 25 (9) | 20.8 (10) | 9.3 (5) | 19.3 (31) |
| A recommendation | 34.8 (8) | 33.3 (12) | 43.8 (21) | 25.9 (14) | 34.2 (55) |
| M recommendation | 17.4 (4) | 19.4 (7) | 12.5 (6) | 29.6 (16) | 20.5 (33) |
| No recommendation | 17.4 (4) | 22.2 (8) | 22.9 (11) | 35.2 (19) | 26.1 (42) |
| 100 (161) |
Figure 4Within each severity group, the percentage of patients classified by recommendation is shown. Note that the total for each severity level is 100%.
Figure 5Histograms showing the number of patients for whom the MAD YES/NO recommendation (a) and SAM recommendation (b) were made. No: not recommended; S: single use; A: alternative treatment; M: multiple treatment approach.
Figure 6Percentages of advancement (in black) to obtain response to mandibular advancement, and percentage of patients (in white) who responded to each percentage of advancement in each severity group (a) Snorers; (b) Mild OSA; (c) Moderate OSA, and (d) Severe OSA).